文献速递瓣膜外科

Trifecta主动脉生物瓣:单中心1,953例中期结果

Trifecta Aortic Bioprosthesis: Midterm Results in 1,953 Patients From a Single Center.
PubMed 文献 · Ann Thorac Surg · 2018-12-01

单中心回顾性研究纳入2011至2017年接受Trifecta主动脉瓣置换的1,953例患者,总体5年生存率69.8%,择期孤立AVR的5年生存率77.5%;5年免于主动脉瓣再干预率96.4%,免于因结构性瓣膜衰败再手术率98.7%,术后平均跨瓣压差低且中期血流动力学良好。

要点

  • Trifecta瓣膜中期耐久性良好,5年免于结构性衰败再手术率98.7%。
  • 择期孤立AVR患者5年生存率77.5%,5年免于再干预率97.6%。
  • 术后平均跨瓣压差低(术后6.8 mmHg,1年10.1 mmHg)。

核心结论

  • Trifecta瓣膜可安全植入主动脉位置,中期耐久性和血流动力学优良。

研究设计与样本

  • 单中心回顾性研究,纳入2011至2017年接受Trifecta主动脉瓣置换的1,953例患者。

主要发现

  • 总体30天、1年、5年生存率分别为94.9%、89.7%、69.8%。
  • 总体5年免于主动脉瓣再干预率为96.4%,免于因结构性瓣膜衰败再手术率为98.7%。
  • 择期孤立AVR的30天、1年、5年生存率分别为98.6%、94.1%、77.5%。
  • 择期孤立AVR的5年免于再干预率和免于结构性衰败再手术率分别为97.6%和99.1%。
  • 术后平均跨瓣压差为6.8±5.3 mmHg,1年时为10.1±6.2 mmHg。

临床怎么用

  • Trifecta瓣膜可用于主动脉瓣置换,中期耐久性支持其临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The St. Jude Medical Trifecta bioprosthesis (St. Jude Medical, St. Paul, MN) is a bovine pericardial valve mounted on a titanium stent. The objective of this study was to report a single-center experience with the Trifecta aortic valve. METHODS: Patients undergoing aortic valve replacement (AVR) with the Trifecta valve between 2011 and 2017 at a single center were included. The primary outcome was overall survival. Secondary outcomes included operative mortality and morbidity, aortic valve reoperations, and reoperation for structural valve deterioration. Echocardiographic outcomes were evaluated. Multivariable logistic regression models were created to identify predictors of death. RESULTS: The study included 1,953 Trifecta valve implants. Operations included isolated AVR (45% [n = 869]), AVR plus coronary artery bypass grafting (40% [n = 771]), and AVR plus mitral valve operation (13% [n = 254]). Overall survival at 30 days, 1 year, and 5 years was 94.9%, 89.7%, and 69.8%, respectively. Overall freedom from aortic valve reintervention was 96.4% at 5 years, with an overall freedom from reoperation for structural valve deterioration of 98.7% at 5 years. For elective isolated AVRs, survival was 98.6%, 94.1%, and 77.5% at 30 days, 1 year, and 5 years, respectively. The 5-year freedom from aortic valve reintervention and reoperation for structural valve deterioration for elective isolated AVRs was 97.6% and 99.1%, respectively. Overall mean gradients were 6.8 ± 5.3 mm Hg postoperatively and remained low at 10.1 ± 6.2 mm Hg at 1 year. CONCLUSIONS: This is the largest series reporting on outcomes of the Trifecta valve. Our results demonstrate that this valve can be safely implanted in the aortic position with excellent midterm durability and hemodynamics.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kilic A, Sultan I, Navid F, et al. Trifecta Aortic Bioprosthesis: Midterm Results in 1,953 Patients From a Single Center. Ann Thorac Surg. 2018. PMID: 30513317. doi:10.1016/j.athoracsur.2018.10.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。